Research programme: recombinant platelet derived growth factor therapeutics - Trophogen
Latest Information Update: 10 May 2016
At a glance
- Originator Trophogen
- Class Recombinant proteins
- Mechanism of Action Platelet-derived growth factor receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Wounds
Most Recent Events
- 04 Feb 2016 Preclinical trials in Wounds in USA (unspecified route) before February 2016